COVACIN phase 1 clinical trial finds no serious adverse effects
The phase 1 clinical trial findings of Bharat Biotech COVID-19 vaccine has revealed and no serious adverse effects, as stated by the interim report. Around 375 participants were enrolled in the first phase clinical trials of Bharat Biotech’s COVID-19 vaccine of which only one person has shown side-effects that was not reported because of the vaccine.
300 participants were given the vaccine doses whereas 75 volunteers received placebo.
One of the participants was administered the vaccine on July 30, but he was tested positive five days later. He was then hospitalised on August 15 and was discharged after a week. This is not seen in relation to the vaccine.
The vaccine can be stored between 2°C and 8°C. Bharat Biotech have announced the start of phase 3 trials of its Coronavirus vaccine and said that it will involve 26,000 volunteers across India.
Bharat Biotech issued a clarification on December 5 saying that the efficiency of the vaccine can be determined in 14 days after the second dose. The third face trials are double blinded and randomized the 50% of the subjects will receive the vaccine and 50% will receive a placebo.
The health ministry is in full support of the drug company and asserted that they had only taken one dose of the two dose vaccine and so he contracted Covid 19.
The COVAXIN it’s being developed in collaboration with the Indian Council of medical research and national Institute of virology.
READ ANOTHER STORY ABOUT The two dose regime- COVID-19 Vaccine
____________
Want To Make A Change? Let’s Start With Promoting Informed and Unbiased Journalism, Start With Sharing This With All of Your Friends and Family, One Voice Cant Reach the Authorities, But Millions of Voices, CAN!
___________
Penned by Simran Oswal, at Earthlyspeaks
___________
For More News and Entertainment Head on to– earthlyspeaks
